| Description | Bifidobacterium is Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In Bifidobacterium is Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS.... Read More | Cynomolgus Monkey is widely used in medical experiments, especially those associated with neuroscience and disease. This product is isolated from Cynomolgus Monkey fresh bone marrow under sterile conditions. Cells are negative for bacteria, yeast, fungi, mycoplasma, and can be used for a variety of Cynomolgus Monkey is widely used in medical experiments, especially those associated with neuroscience and disease. This product is isolated from Cynomolgus Monkey fresh bone marrow under sterile conditions. Cells are negative for bacteria, yeast, fungi, mycoplasma, and can be used for a variety of applications, including drug discovery, assay validation/development, and immunology based assays.... Read More | This product is a 93.2 kDa Human SLC13A3 membrane protein expressed in In vitro wheat germ expression system with proprietary liposome technology. The protein is for research use only and is not approved for use in humans or in clinical diagnosis. | Recombinant Norovirus GI.1 Virus-like Particles (NoV GI.1 VLPs) are produced in Baculovirus/Insect cell expression system, assembled with VP1 structure protein. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material Recombinant Norovirus GI.1 Virus-like Particles (NoV GI.1 VLPs) are produced in Baculovirus/Insect cell expression system, assembled with VP1 structure protein. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material which makes them non-infectious, unable to replicate and enhance the safety during manufacture and administration. NoV GI.1 VLPs can be used in the development of NoV GI.1 diagnostics and in vaccine development and R&D (including use as an immunogen).... Read More | The product SIRGT83828WQ-2MOE is a type of small interfering RNA (siRNA) that targets Rfc4 gene and regulates the expression of gene. The siRNA interferes with the expression of Rfc4 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNAThe product SIRGT83828WQ-2MOE is a type of small interfering RNA (siRNA) that targets Rfc4 gene and regulates the expression of gene. The siRNA interferes with the expression of Rfc4 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNA is designed with 2'-O-methoxyethyl (2'-MOE) modification to provide increased stability, increased specificity and reduced immunogenicity. It has potential applications in RNA interference (RNAi) and gene therapy development.... Read More |